Pirolam

Quick links to important sections

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Pirolam

Property Description
Active Ingredient Ciclopirox (or Ciclopirox olamine)
Pharmacological Class Antifungal Agent (N-hydroxypyridone)
Primary Route Topical (Local dermatological application)
Common Forms Nail Lacquer, Cream, Gel, Shampoo, Solution
Origin Synthetic Compound

What is Pirolam and What Class of Medicine is it?

Pirolam is a pharmaceutical preparation classified as a broad-spectrum antifungal agent intended for topical dermatologic treatment. The medicinal identity of Pirolam is defined by its single active ingredient, Ciclopirox, or its salt, Ciclopirox olamine.

Ciclopirox is a synthetic compound structurally belonging to the N-hydroxypyridone class of antifungals. This chemical group structurally distinguishes it from other common antimycotic groups, such as the azoles or allylamines. Pirolam is clinically recognized for its efficacy against superficial infections, serving as a reliable option where targeted, localized treatment is necessary.

Pirolam's Composition and Available Forms

The core composition of Pirolam centers on Ciclopirox, which is consistently incorporated into various base vehicles for topical administration. The medicine is manufactured in multiple specialized dosage forms to ensure optimal delivery to different infection sites, a feature intended for treating various forms of mycoses.

These forms include medicated nail lacquer (nail polish), topical cream, gel, shampoo, and topical solution. The inclusion of the nail lacquer form is a distinguishing feature of Ciclopirox preparations, specifically engineered to penetrate the dense keratin structure for the management of nail infections. This variety ensures the appropriate application method for conditions requiring surface treatment versus deeper penetration, maintaining a single-active ingredient product profile across all formulations.

What is the General Purpose of Pirolam?

The general purpose of Pirolam is the localized clearance of fungal infections (mycoses) and the control of the organisms responsible for their spread. It achieves this through a mechanism that results in both fungistatic (halting reproduction) and fungicidal (killing the cells) activity. Ciclopirox is effective against a wide variety of yeasts and filamentous fungi by disrupting key cellular activities. This capability provides a defined therapeutic benefit, as it works effectively to resolve the infection at the site of application.

Regulatory References

  1. Ciclopirox Topical: MedlinePlus Drug Information (NIH)

What side effects are possible with Pirolam?

Possible Side Effects and Safety Information

The safety profile of Pirolam (Ciclopirox) is defined by its potential for local reactions and specific restrictions as documented in official regulatory labeling. This information is based strictly on governmental reports and does not constitute medical advice or instructions for use.


Adverse Reactions

The most common reported adverse reactions (occurring in approximately 1–4% of users in clinical studies for some formulations) are localized and include burning, pruritus (itching), erythema (redness), and general irritation at the application site. Post-marketing reports (incidence frequency not established) have noted temporary hair discoloration and abnormal hair texture with the shampoo formulation.

Clinically significant reactions that require immediate discontinuation include signs of a serious allergic reaction (e.g., rash, swelling of the face, tongue, or throat) or severe local chemical irritation or sensitization (e.g., blistering, excessive swelling, or oozing).


Safety Restrictions and Limitations

Contraindications

The medicine is contraindicated for use in individuals with a known hypersensitivity to Ciclopirox or any of the inactive ingredients present in the formulation.

Population-Specific Safety

  • Pediatric Use: Safety and effectiveness are not established in children younger than 10 years (or younger than 16 years for the 1% shampoo formulation).
  • Pregnancy and Nursing: Use during pregnancy is restricted to when it is clearly needed, as adequate and well-controlled studies in pregnant women are not available. Caution is advised when administered to a nursing woman, as it is unknown if the drug is excreted into human milk.

Use Limitations

The medicine is not for ophthalmic use and must be kept away from the eyes. Additionally, the use of occlusive wrappings or dressings on the treatment area should be avoided.

Overdose and Emergency Response

Overdose and when to seek help

The official regulatory documentation for topical Ciclopirox (Pirolam) focuses on the required emergency actions following accidental ingestion and the expected local effects of over-application. The risk of severe systemic overdose is primarily linked to the circumstance of accidental oral ingestion, as the product is intended for external use only.

Documented Overdose Manifestations

Classification Manifestation as Stated in Official Sources
Local Effects Increased skin irritation, including redness, burning, swelling, or blistering at the application site, resulting from excessive topical use.
Systemic Effects Transient headache and drowsiness linked to overexposure from the inhalation of high concentrations of product vapors (solvent components).

Required Emergency Actions

The most critical guidance in official labeling is the requirement to seek immediate medical attention following any known or suspected overdose. Regulators unequivocally state that a doctor or Poison Control Centre must be contacted right away following accidental swallowing of the topical product, regardless of the presence of symptoms. Management procedures officially involve providing symptomatic and supportive treatment; no specific antidote is known or cited in the regulatory information. Hospital monitoring or observation may be required as determined by medical staff.

Therapeutic Uses of Pirolam

Pirolam, containing the broad-spectrum antifungal agent Ciclopirox, is commonly used to manage a range of skin, nail, and scalp conditions that involve fungal and yeast pathogens. The medication is used in clinical settings marked by increased discomfort, providing supportive symptomatic relief.

Its core therapeutic focus is applied across domains involving symptomatic distress from dermatophyte infections (such as athlete's foot and ringworm), cutaneous candidiasis, Pityriasis versicolor, and seborrheic dermatitis. The treatment contributes to improved comfort by addressing symptom clusters that include intense itching, burning, redness, and skin peeling.

In the context of the nails, it is generally used for mild to moderate fungal infections (onychomycosis), helping to ease the burden of structural manifestations like thickening and discoloration. Pirolam is commonly used when short-term symptomatic assistance is needed to help ease discomfort related to superficial infections. This support helps ease the overall symptom load and may assist with maintaining functional stability during periods of heightened symptoms.

Quick Fact: Relief for Inflammation and Irritation

Regulatory References

  1. NIH MedlinePlus Drug Information

Eligibility and Restrictions for Use

The regulatory profile for Pirolam (Ciclopirox) strictly defines who is eligible to use the medicine. The absolute prohibition is for individuals with a known hypersensitivity to ciclopirox or any of the product's components.

Eligibility is highly dependent on age and the specific formulation used. The cream and suspension forms are generally considered established for patients 10 years of age and older. However, for the gel and shampoo formulations, safety and effectiveness have not been established in children younger than 16 years. Similarly, the use of the Nail Lacquer formulation is not established for any pediatric age group.

Regarding special physiological states, Pirolam is classified as Pregnancy Category B. Official documents state that use during pregnancy is conditional and only justified if the potential benefit outweighs the potential risk to the fetus. It is not known if the drug is excreted in human milk, and caution is advised during lactation.

The official prescribing information also notes a specific limitation for the Nail Lacquer formulation, as its effectiveness and safety have not been studied in patients with a history of immunosuppression (such as organ transplant recipients). No explicit restrictions related to hepatic or renal impairment are documented for topical use.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The official interaction profile for Pirolam, containing the topical antifungal agent Ciclopirox, is structured by its minimal systemic exposure and localized application. Due to the very low amount of medicine that enters the bloodstream, regulatory authorities report that no clinically significant systemic drug-drug interactions are known or expected with concurrently administered oral or injectable medicines. This low systemic absorption profile means that interactions involving metabolic enzymes (such as CYP) or drug transporters are not documented in the official prescribing information.

The primary constraints documented in regulatory labels relate to local use and co-administered topical products.

Interaction Scope Official Regulatory Statement
Systemic Drug Interaction Not expected with oral or injectable medicines.
Product-Use Restriction Nail polish or other nail cosmetic products must not be applied to the nails while they are being treated with Ciclopirox nail lacquer.
Co-administration Caution Co-administration with systemic antifungal agents for onychomycosis is not recommended due to a lack of data confirming no reduction in their effectiveness.
Food, Alcohol, Supplements No specific interactions with food, alcohol, or herbal products are documented in regulatory sources.

This structure confirms that the risk of pharmacokinetic interaction with systemic medications is negligible, placing emphasis on the necessary local restrictions for topical product application.

Mechanism of Action

The mechanism of action for the active ingredient, Ciclopirox, involves the simultaneous disruption of critical biological processes within the fungal cell, leading to cellular destruction, complemented by an interaction with surrounding host tissue.


Energy and Metabolic Collapse in Fungal Cells

This domain covers the primary fungicidal action where the drug targets the fungus's fundamental metabolic and energy production pathways. Ciclopirox is a chelating agent that sequesters essential metal cofactors, primarily ferric iron ( Fe^3+), inactivating key fungal enzymes like catalase and peroxidase. Simultaneously, the molecule directly inhibits Complex III of the mitochondrial electron transport chain, leading to acute ATP (energy) deprivation. This metabolic failure, combined with the buildup of toxic peroxides, corresponds to the halting of fungal growth (fungistatic effect) and results in cellular destruction (fungicidal effect).


Modulation of Local Inflammation and System Constraints

The mechanism includes a secondary interaction with the host's physiological pathways, exhibiting a complementary action. Ciclopirox acts as an inhibitor of Cyclooxygenase (COX) and 5-Lipoxygenase (5-LOX) enzymes in human cells, which significantly reduces the local production of inflammatory mediators like prostaglandins and leukotrienes. This process corresponds to the modulation of the body's acute inflammatory response. The overall efficacy of the mechanism is physiologically constrained by penetration barriers, where dense tissues like the nail plate limit the rate at which the active molecule can reach and concentrate within the fungal target cells.

Dosage and Administration Information

How to Use Pirolam

Pirolam, containing the antifungal agent Ciclopirox, is administered exclusively via the topical route for dermatologic use, and is not used for ophthalmic, oral, or intravaginal application. The usage pattern is dependent on the specific formulation being used, with different application techniques, frequencies, and treatment durations.


Administration Guidelines

Administration Scope General Requirement
Route of Administration Strictly Topical (Dermatologic application).
Dosing Frequency Varies by form: Twice daily for creams/gels; Once daily for nail lacquer; Twice per week for shampoo.
Preparation/Technique Suspension must be shaken vigorously before use. Shampoo requires lather to be left on the scalp for three minutes before rinsing.
Special Procedural Conditions Avoid occlusive dressings. Nail lacquer use requires monthly removal of unattached, infected nail and weekly removal of the product with alcohol.
Age Restrictions Cream/Suspension: Not established for children under 10 years. Nail Lacquer: Not established for pediatric use.

Course Duration and Use Protocol

The total treatment time is defined by the specific condition being addressed. For most skin infections (e.g., tinea, candidiasis) using creams or suspensions, the course is generally continued for 4 weeks. Treatment for nail infections with the 8% nail lacquer, however, requires a significantly longer duration, potentially up to 48 weeks of daily application. These guidelines define the administration method to ensure use is confined to the application parameters.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Pirolam

Evidence for Use in Fungal Skin and Nail Infections (Dermatophytoses, Onychomycosis)

This section will summarize existing research and clinical studies on how Pirolam has been evaluated in research settings that studied common fungal infections of the skin (such as ringworm, athlete's foot) and nails.

Research has mainly explored conditions characterized by fluctuating or episodic manifestations on the skin and nails. Research examined outcomes related to physical discomfort and outcomes linked to inflammatory or irritative states in these settings. The data show patterns related to how symptoms evolved in the observed populations over defined time intervals. Findings describe patterns observed in the studies related to conditions involving periods of heightened symptoms on the skin.

Specifically for nail infections (onychomycosis), Pirolam was evaluated in research that studied conditions marked by functional limitations. Research has explored outcomes reflecting daily functioning or activity level that were measured in studies involving these infections. The evidence contributes to the broader evidence landscape by providing context about how patients reported their experience during the study period. However, comparative evidence is lacking, and data for certain groups remain insufficient.

Evidence for Use in Yeast Infections (Candidiasis)

This part will focus on available study data concerning Pirolam's use in research settings that studied infections caused by yeasts, particularly those related to Candida species on the skin or mucous membranes.

Pirolam was evaluated in settings related to yeast-based infections, which are conditions where symptoms may vary in intensity. Studies focused on outcomes related to systemic or functional imbalance that occur with the yeast overgrowth. The research examined temporary physiological imbalance and outcomes capturing phases of heightened symptom activity. Findings help contextualize how patients reported their experience when dealing with these types of infections.

Research describes how symptoms evolved in the observed populations, and research provides insight into short-term changes. Results apply only to the populations studied, and sample sizes were modest in some of the evidence available.

Long-term Studies and Follow-up

This section will summarize what published research reports about extended observation of Pirolam, focusing on the durability of the response after treatment is complete and outlining any data available from studies that followed participants for longer periods.

Research exploring short-term symptom changes was observed in studies, but long-term effects are not fully established. Follow-up durations were limited in the majority of available research. The evidence contributes to understanding symptom patterns over the defined time intervals observed in the studies. However, there is limited information for long-term outcomes, and certainty remains low regarding the durability of findings beyond the observation window of the studies.

Evidence in Special Populations

This segment will outline studies that have specifically evaluated Pirolam in different groups, such as children, older adults, or individuals who have other health conditions (comorbidities), highlighting any populations where evidence is currently limited.

Research has explored Pirolam in research settings involving specific populations, such as children. Data show patterns related to outcomes related to physical discomfort in this younger group, but the overall evidence for this population is limited. For older adults, Pirolam was evaluated in studies, but the evidence quality varies across studies, and data for this group remain insufficient for a robust conclusion.

For individuals with comorbid conditions (other pre-existing health issues), studies exploring outcomes describing episodic or acute changes was observed in some studies. However, subgroup findings are uncertain, and results apply only to the populations studied in the research.

What is Still Uncertain about Pirolam

This final section will synthesize and clearly state the main gaps in the current research, including any areas where study results have been inconsistent or where more research is necessary to fully understand the product's profile.

Evidence highlights what is known — and what is still uncertain. Findings were mixed in some studies, particularly those focusing on conditions presenting with cycles of stability and flare-ups. The research provides context but not individual predictions, and studies contribute to the broader evidence landscape without determining whether an individual will respond similarly.

The main gaps are that long-term effects are not fully established, and comparative evidence is lacking against other types of products sometimes used for the same conditions. Research is ongoing in several areas, but the data are still emerging, meaning a complete picture requires more time and study.

Key Studies & References

  1. Ciclopirox and Ciclopirox Olamine: Antifungal Agents in Dermatology with Expanding Therapeutic Potential - MDPI
  2. Systematic review of topical treatments for fungal infections of the skin and nails of the feet
  3. Safety Study of Ciclopirox Olamine Cream for Dermatomycoses in Children - ClinicalTrials.gov (NCT01646580)

Frequently Asked Questions (FAQ)

Common questions about Pirolam (FAQ)

Q: How quickly do the effects of Pirolam usually start?

A: According to official product information, clinical improvement for certain topical applications, including the relief of symptoms, usually occurs within the first week of starting treatment. However, the time it takes for full symptom resolution varies and depends on the specific fungal infection being addressed.

Q: How long does a course of Pirolam treatment typically last?

A: The required treatment duration is defined by the official instructions for the specific formulation being used and the condition being addressed. For most skin infections, the course is generally continued for the full prescribed period, often up to four weeks. Treatment for nail infections with the lacquer form typically requires a significantly longer duration, potentially up to 48 weeks, to achieve the labeled usage goal.

Q: How long after using Pirolam can I use cosmetics or moisturizers?

A: Regulatory restrictions primarily focus on the nail lacquer formulation, which strictly prohibits the use of nail polish or other cosmetic nail products on the treated nail. Official documents do not explicitly define a specific post-application time constraint for general topical cosmetics or moisturizers applied to the skin.

Q: What happens if I stop using Pirolam too early?

A: Official patient information advises that the medicine is intended to be used for the full treatment time, even if symptoms begin to improve quickly. If treatment is stopped too soon, regulatory information indicates that there is a possibility that the symptoms may return.

Q: How is the safety of Pirolam monitored after it is released?

A: The safety of the medicine is continuously monitored by regulatory bodies. This process involves reviewing reports received from the post-marketing experience—the period after the medicine has become available to the public—which complements the data gathered during the initial pre-approval clinical trials.

Q: Are there any published studies on the use of Pirolam in children?

A: Safety and effectiveness are not established in certain age groups, depending on the specific formulation. For example, official documents state that the cream and suspension forms are not established for children younger than 10 years, and the shampoo/gel forms are not established for those younger than 16 years. The nail lacquer's safety has not been established for any pediatric age group.

Q: Can pregnant women use Pirolam?

A: Official documents classify Pirolam in Pregnancy Category B. This designation indicates that use during pregnancy is conditional and only justified if the potential benefit is clearly judged to outweigh the potential risk to the fetus.

Q: Is it common for side effects from Pirolam to only appear after several days?

A: The most frequent experiences, such as a temporary burning or stinging sensation, may occur immediately upon application. However, patients are advised to inform a healthcare professional if signs of increased local irritation or sensitization, like blistering, excessive swelling, or oozing, appear at any time during the course of treatment.

Q: Can Pirolam be used on different parts of the body?

A: The medicine is indicated for use on the skin for conditions like tinea infections and cutaneous candidiasis, and for the scalp for seborrheic dermatitis, based on the specific formulation used. It is strictly for topical application and is not approved for ophthalmic (eye), oral, or intravaginal use.

Q: Is it normal to feel a mild stinging when first applying Pirolam?

A: Yes, a transient burning or stinging sensation upon application may occur with some formulations. For instance, in clinical trials for the gel formulation, a burning sensation was reported in a notable percentage of patients with tinea pedis and seborrheic dermatitis. This sensation is often described in regulatory reports as transient.

Q: Are there any common reasons why Pirolam might not work for someone?

A: Regulatory instructions state that if a patient shows no clinical improvement after four weeks of treatment for a skin infection, the diagnosis should be reviewed. This suggests non-response is a possibility in some cases, and the effectiveness is dependent on the agent reaching the fungal target cells as intended.

Q: What should I do if I miss an application of Pirolam?

A: According to official patient information, if an application is missed, it is intended to be applied as soon as possible. If it is almost time for the next scheduled application, the missed application should be skipped, and the regular schedule should be continued.

Q: Is it possible to be allergic to Pirolam?

A: Yes, Pirolam is officially contraindicated (prohibited) for use in individuals who have a known hypersensitivity, or allergic reaction, to the active ingredient Ciclopirox or any of the inactive ingredients in the product. Signs of a serious allergic reaction require immediate medical attention.

Q: Are there any foods or drinks that should be avoided while using Pirolam?

A: Due to its localized topical application and minimal systemic absorption, official regulatory sources do not document any specific, known interactions with food, alcohol, or herbal products that should be avoided.

Q: Can Pirolam cause skin discoloration?

A: Post-marketing reports for the shampoo formulation have noted temporary hair discoloration and abnormal hair texture. Official documents advise that severe, unusual discoloration of the skin or nails is a signal that a healthcare professional should be contacted.

Q: Is it true that Pirolam is used for scalp conditions?

A: Yes, Pirolam is available in a shampoo formulation which is specifically approved for the treatment of seborrheic dermatitis of the scalp.

Q: Is there a specific way to prepare the skin before applying Pirolam?

A: Official patient information often recommends gently massaging the gel or cream into the affected area immediately after cleaning or washing the area to be treated. For conditions like athlete's foot, carefully drying the feet, especially between the toes after bathing, is also recommended before application.

Q: Does Pirolam have different names in other countries?

A: Yes, the active ingredient Ciclopirox is marketed globally under various brand names, depending on the country of regulation. Pirolam is a brand name used in Poland, but the same active ingredient is found in products such as Loprox and Penlac in other international markets.

Q: Can Pirolam be used for very mild skin irritation?

A: The official purpose of Pirolam, as defined by its regulatory indications for use, is the localized treatment of diagnosed fungal infections, such as tinea infections, cutaneous candidiasis, and seborrheic dermatitis. It is not indicated for general or very mild non-fungal skin irritation.

Q: What are the typical ingredients besides the active substance in Pirolam cream?

A: In addition to the active ingredient, Ciclopirox, the base cream may contain various inactive ingredients such as propylene glycol, glycerol, carbomer, and trolamine. The exact composition and inactive ingredients can vary by the specific formulation and manufacturer.

Q: Is Pirolam safe to use on sensitive skin areas?

A: The most frequent adverse experience with the product is a transient burning or stinging sensation, which may be more noticeable on sensitive areas. If increased irritation or sensitization, such as excessive redness or swelling, occurs, the official product information indicates that the use of the medication may need to be stopped.

Q: What if I accidentally get Pirolam in my eyes?

A: The medicine is strictly for external dermatologic use only, and contact with the eyes should be avoided. Official patient information advises that if the product accidentally gets into the eyes, they are intended to be rinsed immediately with plenty of cool tap water.

Q: Does Pirolam require special storage conditions?

A: Yes, regulatory guidelines require the product to be stored at a controlled room temperature, typically between 20 C and 25 C (68 F to 77 F). The product must also be kept away from heat, moisture, and direct light, and should be protected from freezing. The nail lacquer formulation is specifically noted as being flammable.

Q: Can men and women use Pirolam in the same way?

A: Official regulatory labels define dosage and usage based on factors such as age, the specific formulation, and the condition being treated. No documented distinction in the application protocols between adult males and adult females is noted for treating the same type of fungal infection.

Q: Are there specific symptoms that signal I should stop using Pirolam?

A: Official documents state that if signs of a serious allergic reaction, such as a rash or swelling of the face, tongue, or throat, or if severe local irritation occurs, the use of the product should be stopped. This includes blistering, excessive swelling, or oozing at the application site.

Q: Is it possible to use too much Pirolam?

A: Since the product is for topical use, it is generally considered non-toxic. However, using excessive amounts may sometimes cause local skin irritation. Official guidance emphasizes that the product is intended to be applied exactly as directed.

Q: Can Pirolam be used to prevent infections?

A: The regulatory purpose of Pirolam, as defined by its official indications for use, is for the treatment of specific, diagnosed fungal infections of the skin, nails, and scalp. It is not approved or indicated for the prevention of these infections.

Q: What is the expected timeline for improvement when using Pirolam?

A: For most skin infections, clinical improvement, including the relief of symptoms, is usually seen within the first week of treatment. It is important to remember that achieving this initial improvement does not mean the infection is cleared; the full, long treatment course is required to fully eliminate the infection.

How should Pirolam be stored and disposed of?

Storage and Disposal Requirements

Pirolam (Ciclopirox) must be stored under specific environmental and container conditions to maintain its stability, as required by regulatory labeling.

Storage Category Official Requirement
Temperature Store at Controlled Room Temperature (20 C to 25 C).
Protection Keep away from heat, moisture, and direct light; must not freeze.
Container Store in a closed container; Nail Lacquer must be kept tightly closed in its carton.
Safety Keep the medication strictly out of the reach of children.
Flammability The Nail Lacquer is flammable and must be kept away from heat and open flame.

Outdated or unused medicine should not be kept. All disposal of the product must be conducted safely and in compliance with applicable local regulations for discarding medicinal waste.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Pirolam found in:

A-Z Index: